메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한골다공증학회 OSTEOPOROSIS OSTEOPOROSIS 제7권 제2호
발행연도
2009.1
수록면
65 - 74 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Osteoporosis, which has been defined by WHO as low bone mineral density(BMD) as that T-score are 2.5 standard deviations(SD) or more below the young-adults, is one of the major health problems particularly among the older men and postmenopausal women. WHO has defined osteoporosis using BMD of postmenopausal Caucasian women as T≤-2.5. It is recommended that BMD measurement is not for routine screening, but for those indicated. Maximum peak bone mass is an important factor for bone health and is mostly genetically determined. Nevertheless, sex hormone, particularly E-2, is important in peak bone mass acquisition and age related bone loss. Hormone therapy can increase BMD and reduce fracture risk in hypogonadal men and women. Constitutionally, men have greater peak bone mass and larger bone than women. In addition, hormone decline rapidly with menopause and gradually with andropause. Thus, aging bone loss accelerates earlier in women(50 y/o) than in men(70 y/o) and more osteoporosis in women than in men. These result in more osteoporotic hip fracture in women, but higher post-fracture mortality in men. The North American Menopause Society(NAMS) has developed guidelines recommending that drug therapy should be considered in: 1) All postmenopausal women who have had an osteoporotic vertebral fracture. 2) All postmenopausal women with BMD values consistent with osteoporosis(i.e., T-score ≤-2.5). 3) All postmenopausal women with T-score from -2.0 to -2.5 plus low body weight, history of fragility fracture since menopause, or a history of hip fracture in a parent. Further, it has been agreed that there is no definitive information for determining which drug for which patient to use. The decision of which drug to use should be made individually for each patient based on those information, such as, risk vs benefit, compliance, patient preference, and may be insurance coverage.

목차

등록된 정보가 없습니다.

참고문헌 (25)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0